Added 4 days ago Drug news

Phase III study of Crysvita meets primary endpoint in X-linked hypophosphatemia.- Ultragenyx Pharma/Kyowa Hakko Kirin.

Ultragenyx Pharmaceutical, Kyowa Hakko Kirin, and Kyowa Kirin International announced that the Phase III study of Crysvita (burosumab) met its...

Added 27 days ago Drug news

Orexigen Therapeutics sells assets to Nalpropion Pharmaceuticals, Inc..

Orexigen Therapeutics, Inc announced that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially...

Added 27 days ago Drug news

NEOD 001 development is discontinued for AL Amyloidosis.-Prothena Corpn.

Prothena Corporation plc has announced that the Company is discontinuing development of NEOD 001, an investigational antibody that was being...

American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and the American College of Endocrinology...

Added 1 year ago

European Guidelines for Obesity Management in Adults

Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting not only adults but also children and adolescents...

Added 2 years ago

Preventing excess weight gain

This guideline covers behaviours such as diet and physical activity to help children (after weaning), young people and adults maintain a healthy weight or help prevent excess weight gain.

Added 3 years ago

Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.

This retrospective, exploratory analysis of data from phase 3 clinical trials of velaglucerase alfa in patients with type 1 GD evaluated the potential of lyso-Gb1 as a specific and sensitive biomarker for GD.

Added 3 months ago

Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

Gaucher disease is an inherited metabolic disease characterized by β-glucocerebrosidase deficiency and commonly treated with enzyme replacement therapy (ERT). The efficacy of ERT with velaglucerase alfa was assessed based on...

Added 3 months ago

Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.

Background: Fabry patients on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in estimated glomerular filtration rate (eGFR) and an increase of the Mainz Severity Score Index.

Added 3 months ago

CARAT: Canagliflozin vs. placebo for post bariatric patients with persistent type 2 diabetes

This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs. placebo on clinical outcomes of type 2 diabetes.

Added 1 year ago

Setmelanotide for the treatment of early-onset POMC deficiency obesity

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight and other factors in patients with pro-opiomelanocortin (POMC) deficiency obesity due to rare bi-allelic loss-of function POMC or PCSK1 genetic mutations.

Added 1 year ago

Division-less gastric bypass, step to decrease cost and early nightmare of bariateric surgery

The purpose of this study is to determine the efficacy of of gastric bypass without gastric division as a treatment for morbid obesity.

Added 1 year ago